Chemomab Therapeutics
CMMB
5 hedge funds and large institutions have $1.29M invested in Chemomab Therapeutics in 2020 Q2 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, 0 reducing their positions, and 1 closing their positions.
195% more capital invested
Capital invested by funds: $437K → $1.29M (+$854K)
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
25% more funds holding
Funds holding: 4 → 5 (+1)
0.02% more ownership
Funds ownership: 0.02% → 0.04% (+0.02%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MIH
Meitav Investment House
Bene-Beraq,
Israel
|
+$387K |
| 2 |
RC
RegentAtlantic Capital
Morristown,
New Jersey
|
+$26.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PCM
1
Palisade Capital Management
Fort Lee,
New Jersey
| $506K | – | – | – |
|
|
MIH
2
Meitav Investment House
Bene-Beraq,
Israel
| $500K | +$387K | +5,698 | New |
|
|
AIC
3
AWM Investment Company
New York
| $217K | – | – | – |
|
|
PF
4
Phoenix Financial
Givatayim,
Israel
| $34K | – | – | – |
|
|
RC
5
RegentAtlantic Capital
Morristown,
New Jersey
| $34K | +$26.5K | +391 | New |
|
|
6
UBS Group
Zurich,
Switzerland
| – | -$2K | -34 | Closed |
|
CMMB Hedge Fund Activity: Q2 2020 in Review
5 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Chemomab Therapeutics (CMMB) for Q2 2020, worth a combined $1.29M — up 195% from $437K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new CMMB positions and 1 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Meitav Investment House, opening a new position worth an estimated $387K. The largest seller was UBS Group, exiting entirely with an estimated $2K sold.
- 5 institutional investors held Chemomab Therapeutics (CMMB) as of Q2 2020, up from 4 in Q1 2020.
- Funds reported $1.29M of Chemomab Therapeutics stock for Q2 2020, up 195% quarter-over-quarter.
- 2 funds opened new Chemomab Therapeutics positions in Q2 2020 and 1 closed out, a net change of +1 holder.
- The largest Chemomab Therapeutics buyer in Q2 2020 was Meitav Investment House, an estimated $387K added.
- The largest Chemomab Therapeutics seller in Q2 2020 was UBS Group, an estimated $2K sold.
Based on aggregated 13F filings for Q2 2020.